Sharemaestro Newsreel

Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap

A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The …

Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding

Citadel-affiliated entities and Kenneth Griffin have reported a beneficial ownership of 3.5% in Pliant Therapeutics (PLRX) common stock through an amended Schedule 13G/A filing. This includes 2,143,426 shares owned by Kenneth Griffin, calculated based on 61,920,249 outstanding shares as of May 8, 2026. Various …

Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts

Caribou Biosciences (NASDAQ:CRBU) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.75. The company's shares recently traded down 2.2% to $1.57. Caribou Biosciences reported a narrower-than-expected quarterly loss but missed revenue estimates, and institutional investors own …

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

Caribou Biosciences (NASDAQ: CRBU) reported second-quarter EPS of $-0.240, beating analyst estimates by $0.07, and revenue of $2.65 million, surpassing the consensus estimate of $2.3 million. Despite the earnings beat, the company's stock price has declined by -24.770% in the last three months and …

Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M

Replimune Group, Inc. reported a Q1 net loss of $69.8 million but secured FDA accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for advanced cutaneous melanoma. The company also raised $141.0 million in net proceeds from an August 2026 equity offering, extending …

Cerenome (PSTV) burns cash, warns on going concern despite fresh equity

Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have reported an amended passive ownership of 3.6% in CytomX Therapeutics, Inc. (CTMX) common stock, totaling 7,811,033 shares as of June 30, 2026. This stake is held indirectly through an investment fund managed by …

PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake

PureTech Health plc, along with its affiliates, has reported a beneficial ownership of 31.2% in Seaport Therapeutics, Inc., amounting to 16,685,013 shares of Voting Common Stock. This stake is held by PureTech LYT, Inc., with PureTech Health LLC and PureTech Health plc exercising indirect …

SOLV Energy (MWH) surges in Q2 2026 with $1.63B revenue and no term debt

Pediatrix Medical Group (MD) director receives 472-share restricted stock grant

John M. Starcher Jr., a director at Pediatrix Medical Group (MD), was granted 472 restricted shares of common stock on August 12, 2026. These shares, valued at $26.50 each, are part of the company's incentive compensation plan and will vest on May 7, 2027. …

Pediatrix Medical Group (MD) director awarded 472 restricted shares and reports trust holdings

Pediatrix Medical Group director Thomas McEachin was granted 472 restricted shares of common stock on August 12, 2026, valued at $26.50 per share, under the company's incentive plan. These shares will vest on May 7, 2027. Following this transaction, his direct holdings increased to …

Pediatrix Medical Group (MD) grants 472 restricted shares to director Sansone

Pediatrix Medical Group (MD) director Guy P. Sansone received an equity award of 472 restricted shares on August 12, 2026, priced at $26.50 per share. These shares, granted under the company's Second Amended and Restated 2008 Incentive Compensation Plan, will vest on May 7, …

Concentra Group Holdings Parent Inc stock hits all-time high at 35.16 USD

Concentra Group Holdings Parent Inc. stock has reached an all-time high of $35.16, contributing to a market capitalization of $4.48 billion and marking a 79% year-to-date return. Despite its overvalued status according to InvestingPro, the company demonstrates strong financial health with a Piotroski Score …

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 2.07% on Friday, closing at $505.75, amid a general market decline where the S&P 500 and Dow Jones Industrial Average also saw losses. This marked the third consecutive day of losses for the company's shares.

Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

This article highlights three promising penny stocks for investors' watchlists: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite varying financial statuses—from pre-revenue to strong growth—all three companies are presented with an overview of their operations, market capitalization, and key financial health …

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss

Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock

Alia Mentis Spa: Revenue and Earnings Analysts Forecasts Revisions | ALMS | IT0005717241

Intuitive Surgical (ISRG) Is Facing Fresh Competition In U.S. Surgical Robotics

Intuitive Surgical (ISRG) is facing new competition in the U.S. surgical robotics market as Johnson & Johnson's Ottava system received FDA authorization. Ottava's space-saving design and integration with J&J's existing surgical tools pose a direct challenge to Intuitive Surgical's da Vinci systems, potentially impacting …

NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk

NRx Pharmaceuticals reported its Q2 2026 results, showing significant growth in net patient service revenue to $1.1 million for the quarter and $2.2 million for the first six months, primarily through its HOPE subsidiary's acquired Florida behavioral health clinics. Despite this new revenue stream …

Alaunos Therapeutics (TCRT) warns on cash runway, Nasdaq compliance and losses

Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares

Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G for iBio, Inc. (IBIO), correcting their reported beneficial ownership to include 2,807,016 shares of common stock issuable upon exercise of Series F warrants. This represents a 5.4% stake in iBio, based …

GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes

GT Biopharma shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, and a reduction in authorized shares to 25,000,000 common and 1,500,000 preferred shares. They also approved a 3,500,000-share increase to the 2022 Omnibus Incentive Plan and an evergreen provision for automatic …

InspireMD (NSPR) grows revenue 56% but flags going concern and Nasdaq risk

InspireMD, Inc. reported increased revenues for the first half of 2026, up 56.3% to $5.17 million, driven by U.S. CGuard Prime sales and international growth, despite a voluntary recall of CGuard Prime impacting quarterly revenue and gross margin. The company posted a significant net …

Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes

Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported significant beneficial ownership stakes in Kura Oncology, Inc. Montanova Capital and Aaron Cowen each own 9.7% of the common stock, while Averill Master Fund holds 8.8%. The reported shares are directly owned …

Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock

Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership …

Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding

Femasys Inc. (NASDAQ: FEMY) reported a narrowed net loss of $3.6 million for the first half of 2026, significantly down from $10.5 million in 2025, largely due to non-cash gains from reclassifying conversion options and warrant liabilities. The company secured approximately $30 million in …

Bruker (BRKR) Is Up 13.0% After Cutting 2026 Outlook And Expanding AI Lab Tie-Up With Atinary

Travere Therapeutics (TVTX) On Record FILSPARI Sales And A Fair Value Gap

$XWEL Q2 '26 Earnings Results & Recap

Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results

BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk

Traws Pharma Expects Q3 Resubmission for Flu Antiviral

Citius Oncology's LYMPHIR has 44 ordering institutions, 383 July vials